Table 2.
Results of impedance aggregometric and thrombelastometric assays
| All patients | MELD 6-11 | MELD ≥ 17 | P value | |
| Impedance aggregometry | ||||
| AUCADP1, U (IQR) | 43 (30-56) | 45 (30-56) | 42 (29-67) | 0.80 |
| AUCADP1< 55 U, n (%) | 34 (68) | 17 (68) | 17 (68) | 0.58 |
| AUC ASPI2, U (IQR) | 71 (57-99) | 72 (57-96) | 68 (43-104) | 0.53 |
| AUCASPI2 < 79 U, n (%) | 22 (44) | 12 (48) | 10 (40) | 0.94 |
| AUCTRAP, U (IQR) | 92 (61-106) | 94 (80-109) | 79 (60-110) | 0.26 |
| AUCTRAP < 92 U, n (%) | 24 (48) | 9 (36) | 15 (60) | 0.09 |
| Thrombelastometry | ||||
| EXTEM | ||||
| CT, s (IQR) | 71 (65-79) | 70 (65-77) | 73 (64-81) | 0.52 |
| CT < 42 s, n (%) | 1 (2) | 0 | 1 (4) | 0.10 |
| CT > 74 s, n (%) | 19 (38) | 8 (32) | 11 (44) | 0.38 |
| CFT, s (IQR) | 100 (75-115) | 103 (82-109) | 97 (67-132) | 0.96 |
| CFT < 46 s, n (%) | 1 (2) | 0 (0) | 1 (4) | 0.10 |
| CFT > 148 s, n (%) | 6 (12) | 1 (4) | 5 (20) | 0.18 |
| MCF, mm (IQR) | 57 (51-63) | 58 (53-63) | 52 (46-63) | 0.06 |
| MCF <49mm, n (%) | 10 (20) | 0 (0) | 10 (40) | < 0.001 |
| MCF >71mm, n (%) | 4 (8) | 2 (8) | 2 (8) | 1.00 |
| α-angle, ° (IQR) | 73 (69-77) | 74 (70-76) | 71 (66-80) | 0.31 |
| α-angle < 63°, n (%) | 3 (6) | 0 (0) | 3 (12) | 0.23 |
| α-angle > 81°, n (%) | 4 (8) | 1 (4) | 3 (12) | 0.60 |
| INTEM | ||||
| CT, s (IQR) | 197 (183-226) | 195 (181-217) | 202 (185-230) | 0.80 |
| CT < 137 s, n (%) | 0 (0) | 0 (0) | 0 (0) | a |
| CT > 246 s, n (%) | 9 (18) | 4 (16) | 4 (16) | 1.00 |
| CFT, s (IQR) | 92 (69-110) | 91 (80-109) | 91 (62-120) | 0.55 |
| CFT < 40 s, n (%) | 1 (2) | 0 (0) | 1 (4) | 1.00 |
| CFT > 100 s, n (%) | 22 (44) | 8 (32) | 11 (44) | 0.56 |
| MCF, mm (IQR) | 54 (48-59) | 55 (51-59) | 52 (42-59) | 0.16 |
| MCF < 52 mm, n (%) | 20 (40) | 8 (32) | 11 (44) | 0.38 |
| MCF > 72 mm, n (%) | 1 (2) | 0 (0) | 1 (4) | 1.00 |
| α-angle, °(IQR) | 73 (69-76) | 71 (67-75) | 74 (69-80) | 0.55 |
| α-angle < 71°, n (%) | 19 (38) | 10 (40) | 9 (36) | 0.77 |
| α-angle > 82°, n (%) | 0 (0) | 0 (0) | 0 (0) | a |
| FIBTEM | ||||
| CT, s (IQR) | 63 (56-71) | 59 (55-65) | 68 (59-79) | 0.004 |
| CT < 43 s, n (%) | 0 (0) | 0 (0) | 0 (0) | a |
| CT > 69 s, n (%) | 3 (6) | 4 (16) | 9 (36) | 0.19 |
| MCF, mm (IQR) | 17 (12-20) | 17 (14-20) | 12 (9-21) | 0.11 |
| MCF < 9 mm, n (%) | 4 (8) | 0 (0) | 4 (16) | 0.11 |
| MCF > 25 mm, n (%) | 3 (6) | 0 (0) | 3 (12) | 0.23 |
Data are presented as the median, with 25th-75th percentiles shown within parentheses or count and percentage as indicated. Data comparisons were made with Mann-Whitney U test or χ2 test where applicable. Reference ranges of impedance aggregometric tests for area under the curve (AUC, U) were: AUCADP: 55-117, AUCASPI: 79-141. AUCTRAP: 92-151[23].
One patient on clopidogrel therapy was excluded from analysis;
13 patients on therapy with acetylsalicylic acid were excluded from analysis. P values are given for comparison between MELD 6-11 and MELD ≥ 17 groups.
No statistics were computed because no measured values were within the given range. AUC: Area under the curve; ADP: Adenosine-5 diphosphate; ASPI: Arachidonic acid; TRAP: Thrombin receptor activator peptide 6; MEA: Multiple electrode aggregometry; IQR: Indicates interquartile range; CT: Clotting time; CFT: Clot formation time, MCF: Maximum clot firmness.